Inovio Pharmaceuticals, Inc. — Q3 2014 Form 10-Q
Reporting period: Three and nine months ended September 30, 2014. Inovio is a clinical-stage biotechnology company developing DNA vaccines and immune therapies with electroporation delivery. It had no approved human products and reported no product-sales revenue.
Financial results and liquidity
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Total revenue | $1.84 million | $9.49 million | $8.00 million | $11.73 million |
| Operating income (loss) | $(8.33) million | $0.77 million | $(28.48) million | $(11.54) million |
| Net loss | $(7.18) million | $(30.89) million | $(28.73) million | $(50.62) million |
| Net loss per share, basic | $(0.12) | $(0.64) | $(0.49) | $(1.15) |
| Net cash used in operations | Not separately presented for the quarter | $(21.75) million | $(16.26) million |
- At September 30, cash and cash equivalents were $70.7 million and short-term investments were $30.3 million, totaling $100.9 million. Working capital was $95.7 million.
- Total assets were $134.5 million, total liabilities $17.5 million, and stockholders’ equity $117.0 million. The balance sheet shows no debt line item.
- Nine-month financing provided $71.3 million, including approximately $59.2 million net proceeds from a March stock offering and $12.1 million from option and warrant exercises. Shares outstanding were 60.6 million as of November 3, 2014.
- No meaningful product margin was reported; the company remains research-and-development focused. Nine-month R&D expense rose to $24.9 million from $15.0 million, while G&A increased to $11.6 million from $9.3 million.
Changes versus the prior comparable period
- Revenue fell 81% in Q3 and 32% for the nine-month period. Management attributed much of the comparison to recognition of $8.4 million of Roche upfront-payment revenue in September 2013. Grants and miscellaneous revenue also declined.
- Operating results weakened: Q3 moved from operating income to an operating loss, and the nine-month operating loss widened. Increased clinical, staffing, device-development, and Roche-collaboration costs contributed.
- Reported net loss was lower year over year for both periods, but comparisons were affected by noncash warrant revaluations. The 2013 periods included substantial gains from warrant-liability fair-value changes; these gains were much smaller in 2014. The 2014 nine-month result also included a $0.7 million loss on the GeneOne investment.
- Operating cash use increased to $21.7 million from $16.3 million for the first nine months. Cash and investments nevertheless rose, primarily due to equity financing and warrant and option exercises.
Outlook, commentary, and notable items
- Management expects substantial operating losses to continue. It stated that cash and short-term investments should fund planned working-capital requirements through the end of 2017, excluding the planned Phase III VGX-3100 trial; financing will be needed beyond that period. This is management’s estimate, not a guarantee.
- Roche collaboration revenue was $1.1 million in Q3 and $5.6 million for the first nine months. The agreement includes potential additional development, regulatory, and commercial payments, but no event-based milestones were achieved in the periods presented.
- In September, Inovio and affiliated GeneOne agreed to co-develop an Ebola vaccine through Phase I trials. The filing reports no associated milestone achievement in the period.
- A subsidiary agreed to sell animal-health assets to Plumbline Life Sciences for $2.0 million in staged cash payments and a 20% equity interest. No receivable for the cash payments was recorded because collection was uncertain.
- The company raised capital through a March 2014 public offering and completed a 4-for-1 reverse stock split in June. Its common stock began trading on Nasdaq in September.
- In March, the company entered an 11.5-year office lease; disclosed future minimum lease payments totaled approximately $14.0 million. No material litigation was reported, and management concluded disclosure controls were effective.
- Key risks include clinical-trial and regulatory uncertainty, ongoing losses and future financing needs, reliance on collaborators and government funding, manufacturing constraints, competition, and intellectual-property risks. The filing provides no specific near-term revenue or earnings guidance.
Important facts for investors to verify
- Whether cash burn and development spending remain consistent with management’s stated runway, particularly if the VGX-3100 Phase III trial proceeds.
- Clinical progress, trial funding, and milestone timing for key programs, including VGX-3100 and Roche-partnered candidates.
- Future revenue concentration and the timing and continuity of Roche, grant, and government-contract funding.
- Potential dilution from equity financing, stock compensation, and outstanding warrants and options; also monitor warrant fair-value effects on reported earnings.
- Collection of the Plumbline cash payments and the value and terms of the subsidiary’s equity interest.